Malaria vaccine booster trial aims to keep school kids protected
NCT ID NCT07074665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a booster shot of the R21/Matrix-M malaria vaccine in 40 school-age children in Burkina Faso who already received four doses years earlier. Half get the standard child dose, half get a higher adult dose. Researchers will check for side effects and measure antibody levels over one year to see if a booster is safe and boosts immunity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
R21/Matrix-M malaria vaccine
What this could lead to
If successful, this could show that a booster dose of the R21/Matrix-M vaccine is safe and effective for school-age children, helping to maintain protection against malaria as they grow older.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to all children. The main focus is safety and immune response, not whether it prevents malaria. Side effects like injection site pain or fever are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA (PLASMODIUM FALCIPARUM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Unité de Recherche Clinique de Nanoro (URCN)
RECRUITINGNanoro, PO Box 11 BP 218 Ouaga CMS 11, Burkina Faso
Contact Phone: •••-•••-•••• Email: •••••@•••••